In this Exclusive Interview, Kevin Sayer talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Dexcom G6 CGM System and how the future of CGM will affect the way not only type 1, but also type 2 and prediabetes are treated.
Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research.
He joined Dexcom as President and Chief Operating Officer in 2011. In this executive role, Kevin was responsible for research and development, manufacturing, clinical, regulatory, finance, sales and marketing functions. During his tenure with Dexcom, he has been instrumental in leading the development of new technology, including the Dexcom G5 Mobile CGM System, the Dexcom G4 PLATINUM System with Share and several other product launches in the US and Europe.
Prior to joining Dexcom, Kevin served as Chief Financial Officer of Biosensors International, a medical technology company focused on the development, manufacturing and commercialization of medical devices used in interventional cardiology and critical care procedures.
Kevin also served as CFO of MiniMed, Inc. from 1994 until its acquisition by Medtronic, Inc. in 2001.
Kevin received his master’s and bachelor’s degrees in Accounting and Information Systems from Brigham Young University.
Pt.1: Biography and Introduction
Pt.2: Dexcom G6 CGM System
Pt.3: When Will A CGM Be More Widely Available
Pt.4: Advanced Progression of Prediabetes
Pt.5: Properly Educating Diabetes Patients
Pt.6: How Has Diabetes Patient Care Evolved
Pt.7: What’s Happening In The Future?